Close menu




June 30th, 2022 | 13:49 CEST

Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

  • Biotechnology
Photo credits: pixabay.com

Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

time to read: 5 minutes | Author: André Will-Laudien
ISIN: XPHYTO THERAPEUTICS | CA98421R1055 , VALNEVA SE EO -_15 | FR0004056851 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech - Back at the critical line, where do we go from here?

    76.2% of the German population have received at least one vaccination dose to date. 63.3 million people have thus already received primary immunization, and 51.2 million went for a second shot. Only 5.7 million people, or 6.9%, received a second booster vaccination. As before, 18.5 million people, or 22.2% of the population, have not been vaccinated. With currently only about 50,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf for the time being.

    For the major vaccine manufacturers, future orders will likely decline more sharply, but BioNTech has already been able to negotiate many millions of doses for the fall. With the Corona vaccine, the Mainz-based biotech has not only led its first substance to approval but has also been able to close 2021 with a full EUR 10 billion in profits. Recently, the biotech company published an update on the vaccine candidates adapted to the Omicron variant. The results of the phase 2/3 trial show that the improved vaccine elicits a significantly higher immune response against Omicron BA.1 through booster vaccination compared to the basic version of the blockbuster "Comirnaty". The vaccine is also effective against other Omicron subvariants, but not as strongly as against BA.1.

    The BioNTech share has fallen below the critical EUR 115 line twice due to two sharp downward movements but has always been able to break away from it dynamically. Adjusted estimates attest to a strong decline in sales between 2022 and 2026, but you never know with what achievements the biotech company will come around the corner. From a purely technical point of view, the value should not fall below the line of EUR 115 again; then, the technical hope for better times will remain. Keep watch.

    XPhyto Therapeutics - The bio accelerator could now become interesting

    XPhyto Therapeutics had tried to gain a foothold in the COVID PCR testing market in the fall of 2021. The development ultimately took too long to capture significant market share, and the stock went chart technically into a sell-off. The reason for this was undoubtedly the permanent reporting of low sales in the group because, in the eyes of investors, a market-ready product should at some point provide noticeable revenues after a few years of research.

    The Company's remaining pipeline is still attractive, as it has several products in its quiver from the ODF preparations division of its German subsidiary Vektor Pharma. Using intelligent formulation technologies, Vektor has investigated generic and new active ingredients and developed them into efficient transdermal systems. Locally acting dermal systems are films formulated in such a way that the active ingredient cannot pass into the bloodstream but remains in the skin. Examples include pain patches that are applied just before injections.

    Orally Disintegrating Films (ODF) are bioadhesive films that rapidly disintegrate on the tongue or in the mouth and release active ingredients in the mouth, providing a rapid response. Applications include colds, vitamin supplementation, and emergency situations. Developed ready for the market in 2021, the Company's rotigotine patch is based on the TDS platform technology developed by the German subsidiary. This dosage form is becoming increasingly popular internationally, and the only thing XPhyto lacks here is a suitable distribution partner with clout. According to Research and Markets, the global transdermal skin patch market had already reached a value of nearly USD 6.5 billion by 2020 and is expected to grow to about USD 20 billion by 2028, according to Kuick Research. In addition to this research, the Canadians are also working on evaluating psychedelic agents for treating neurological disorders.

    XPhyto shares now appear to have paused in the recent downtrend. For several days, the price has fluctuated between CAD 0.55 and 0.62, or around EUR 0.42, with good turnover. The trading volume in Germany is sometimes even higher than in Canada due to the high profile of the subsidiaries Vektor and 3a. The current conspicuous turnover could therefore be the harbinger for external interested parties. Keep the stock on your watchlist!

    Valneva versus CureVac - Who can seal the next deal?

    Things are getting exciting again for biotech stocks in the vaccine sector, which have not yet achieved market success. Despite all the delays in the development phase of its dead vaccine, the share of the French-Austrian biotech company Valneva has become one of the best vaccine stocks in 2021, without a broad market launch having taken place. However, a sellout to EUR 7.25 occurred in mid-June when there were renewed delays in the EU approval process. However, EMA approval has now been granted, and Valneva shareholders can breathe a sigh of relief, at least in the short term. The price rally started promptly and catapulted the share price upwards by 70%. Since only the approval has been confirmed so far, it remains to be seen whether the EU will uphold the planned order from 2021.

    CureVac has been very quiet on the Corona vaccine front. It recently announced the acquisition of Frame Cancer Therapeutics; a private company focused on advanced genomics and bioinformatics to identify neoantigens for various cancers. "Embedding Frame's technology and expertise into CureVac's oncology research complements our ability to identify and validate promising neoantigens for our mRNA cancer vaccine programs," said Franz-Werner Haas, chief executive officer of CureVac.

    With the newly developed bioinformatics platform, CureVac has a tool to identify a broad spectrum of neoantigens beyond conventional neoantigens that could help develop highly effective cancer vaccines. Another application of Frame's technology is the development of personalized cancer vaccines, harnessing the full antigenic potential of a tumor. In December 2021, regulatory authorities in the Netherlands approved Frame's clinical trial protocol to evaluate the peptide vaccine-based approach in 15 patients with non-small cell lung cancer. CureVac will now refocus its development of mRNA-based personalized cancer vaccines.

    The stock has already suffered badly in the market with a 77% loss in 12 months but could become interesting again with initial success reports. The speculative investor can quietly collect the title in the current corridor between EUR 12 and EUR 14. However, for this investment, investors need patience and nerves for the medium term.


    The biotech sector thrives on its successes, and the associated shares have always been a hot potato. With the COVID pandemic, there have been big winners and just as many losers. The right investment selection remains an arduous selection process. XPhyto's interesting TDS platform technology may one day also be highly interesting for third parties.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read